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(CL) remain largely unknown. Consequently, expression of the endothelin (ET) receptors-A and -B
(ETA and ETB, revealing vasoconstriction and vasodilator properties respectively), the ET-converting
enzyme (ECE1) and ET1, -2 and -3 were investigated in CL from non-pregnant dogs (days 5, 15, 25,
35, 45 and 65 post-ovulation), and at selected stages of pregnancy (pre-implantation, post-implantation,
mid-gestation), and during normal and antigestagen-induced prepartum luteolysis/abortion. The inter-
relationship between PGE2 and the ET system was investigated in PGE2-treated canine primary lutein
cells from early CL. ET1 did not change significantly over time; ET2, ECE1 and ETB were elevated in
early CL and were downregulated towards the mid/late-luteal phase. The prepartum increase of ET2
was significant. ET3 increased gradually, and was highest in late CL and/or at prepartum luteolysis.
ETA remained constant until the late CL phase and increased only during prepartum luteolysis. ET1
was localized to the luteal cells, and ET2, ET3 and ETA to vascular endothelium. ECE1 and ETB were
detected at both locations. Except for upregulated ET1 and lack of effect on ET2, antigestagen applied to
mid-pregnant dogs evoked similar changes to those observed during normal luteolysis. PGE2 upregulated
ETB in treated cells; ETA and ET1 remained unaffected, and ET2 decreased. A modulatory role of the
ETs in canine CL, possibly in association with other factors (e.g., PGE2 and progesterone receptor), is
strongly indicated.
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Luteal development is regulated by many locally produced mediators, e.g., prostaglandins and 26 
angiogenic factors. However, the role and function of vasoactive factors in the canine corpus 27 
luteum (CL) remain largely unknown. Consequently, expression of the endothelin (ET) 28 
receptors-A and -B (ETA and ETB,, revealing vasoconstriction and vasodilator properties, 29 
respectively), the ET-converting enzyme (ECE-1) and ET-1, -2 and -3, was investigated in CL 30 
from non-pregnant dogs (days 5, 15, 25, 35, 45 and 65 post-ovulation), and at selected stages of 31 
pregnancy (pre-implantation, post-implantation, mid-gestation), and during normal and 32 
antigestagen-induced prepartum luteolysis/abortion. The interrelationship between PGE2 and the 33 
ET system was investigated in PGE2-treated canine primary lutein cells from early CL. ET-1 did 34 
not change significantly over time; ET-2, ECE-1 and ETB were elevated in early CL and were 35 
downregulated towards the mid/late-luteal phase. The prepartum increase of ET-2 was 36 
significant. ET-3 increased gradually, and was highest in late CL and/or at prepartum luteolysis. 37 
ETA remained constant until the late CL phase and increased only during prepartum luteolysis. 38 
ET-1 was localized to the luteal cells, and ET-2, ET-3 and ETA to vascular endothelium. ECE-1 39 
and ETB were detected at both locations. Except for upregulated ET-1 and lack of effect on ET-2, 40 
antigestagen applied to mid-pregnant dogs evoked similar changes to those observed during 41 
normal luteolysis. PGE2 upregulated ETB in treated cells; ETA and ET-1 remained unaffected, 42 
and ET-2 decreased. A modulatory role of the ETs in canine CL, possibly in association with 43 
other factors (e.g., PGE2 and progesterone receptor), is strongly indicated. 44 
 45 
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Introduction  48 
The Corpus luteum (CL) is a highly vascularized, transient endocrine tissue. Its development and 49 
maintenance depend on an adequate blood supply (reviewed in (Fraser & Wulff 2003)). Prior to 50 
ovulation, the basement membrane of growing ovarian follicles constitutes the borderline 51 
between the vascularized and non-vascularized follicular compartments (Suzuki et al. 1998, 52 
Grazul-Bilska et al. 2007, Martelli et al. 2009, Kowalewski et al. 2015). Its rupture during 53 
ovulation is followed by rapid spreading of blood vessels into the follicular antrum and 54 
establishment of a dense vascular network that in mature CL provides virtually every lutein cell 55 
with access to a capillary. Thus, angiogenesis is an important process needed for rapid luteal 56 
formation. It is tightly regulated by numerous locally produced mediators such as angiogenic 57 
factors (Reynolds et al. 2000, Fraser & Wulff 2003, Zalman et al. 2012). Among these, 58 
endothelins (ETs) play an important role in regulating many ovarian functions including 59 
vascularization, steroidogenesis, ovulation and folliculogenesis, as well as luteal regression 60 
and/or luteolysis (Apa et al. 1998, Girsh & Dekel 2002, Ko et al. 2006, Cacioppo et al. 2014). 61 
Endothelial-derived ETs consist of three different isoforms, ET-1, -2, and -3, which convey their 62 
effects through ETA and ETB receptors (Yanagisawa et al. 1988, Nussdorfer et al. 1999). 63 
Although activation of ETA causes a pronounced vasoconstriction, ETB receptor occupation 64 
results in vasodilatation by induction of the nitric oxide pathway (Yanagisawa & Masaki 1989). 65 
While ETA has a very high affinity for ET-1 and ET-2, ETB has a similar affinity to all the 66 
endothelin types (Nussdorfer et al. 1999). ET-2 is the only endothelin that is upregulated in pre-67 
ovulatory follicles at the time of ovulation and, as suggested for humans, rats and mice, its 68 
elevated levels might result from the hypoxic condition observed within growing follicles (Ko et 69 
al. 2006, Na et al. 2008, Bridges et al. 2010, Choi et al. 2011). The functional importance of ET-70 
2 and ETB for ovulation, CL formation and luteal P4 production was shown in mice (Palanisamy 71 




et al. 2006, Cacioppo et al. 2014). ETs also influence steroidogenesis through the activation of 72 
ETA (Iwai et al. 1991, Tedeschi et al. 1994, Kamada et al. 1995, Girsh et al. 1996). ET-1 was 73 
shown to inhibit LH-, FSH- and hCG- stimulated P4 secretion by porcine, human and rat 74 
granulosa cells, as well as by cultured bovine luteal cells (Iwai et al. 1991, Flores et al. 1992, 75 
Tedeschi et al. 1994, Kamada et al. 1995, Girsh et al. 1996).  Furthermore, as shown in cattle 76 
(Ohtani et al. 1998), ETs seem to be involved in PGF2α-induced luteolysis. Thus, utilizing a 77 
luteal microdialysis system and applying PGF2α in cows, a steep rise in ET-1 concentration was 78 
detected within the regressing CL as well as in the ovarian venous blood (Ohtani et al. 1998). 79 
Similarly, PGF2α injections in sheep, cows and rabbits resulted in elevated luteal mRNA 80 
expression of ET-1 (Milvae 2000, Wright et al. 2001, Boiti et al. 2007). Interestingly, in vivo 81 
blockage of the ETA receptor mitigated the ET-1-mediated luteolytic action of PGF2α in ewes 82 
and cows (Hinckley & Milvae 2001, Watanabe et al. 2006).  83 
In contrast to other mammalian species, none of the above information is available for the dog, a 84 
species in which the maintenance of pregnancy depends entirely upon the luteal secretion of P4 85 
as its only major source, both in pregnant and non-pregnant cyclic animals.  86 
As in other species, following ovulation and formation of the corpus hemorrhagicum, the canine 87 
CL is rapidly vascularized (see review in (Kowalewski 2014)). During this time, PGs, especially 88 
PGE2, are among the most potent luteotropic factors regulating CL functions (Kowalewski et al. 89 
2015). As concluded from the considerably decreased expression of vascular endothelial cell-90 
bound endoglin (Hoffmann et al. 2004a, Hoffmann et al. 2004b), the vascularization rate slows 91 
down by the mid-luteal phase and does not change significantly later on, until the late luteal 92 
phase in non-pregnant bitches. From this, it has been concluded that the reduction of vascular 93 
network density does not seem to be the major factor regulating luteal regression in dogs 94 
(Hoffmann et al. 2004a, Hoffmann et al. 2004b). Corroborating these results, expression of the 95 




vascular endothelial growth factor (VEGF) system also remained unaffected during prepartum 96 
luteolysis (Kowalewski 2014). The initially increased vasculogenic and angiogenic activities are 97 
evidenced by the expression of members of the VEGF system in steroidogenic and non-98 
steroidogenic cells (Mariani et al. 2006, Papa Pde et al. 2013).  99 
In order to fill the existing knowledge gap regarding the potential function of vasoactive factors 100 
in canine CL and, thereby, to better understand the para/autocrine regulatory mechanisms 101 
governing its function, the present study investigated the expression and localization of ET-1, -2 102 
and -3, and of ETA and ETB, as well as of endothelin converting enzyme (ECE-1; responsible 103 
for activating of endothelins) in CL from non-pregnant and pregnant dogs at selected times 104 
during the luteal lifespan. Additionally, in view of PGE2 being one of the most important 105 
luteotropic factors in the dog, the effects of PGE2 on the ET system were investigated in canine 106 
primary lutein cells isolated from early CL. 107 
 108 
Materials and Methods 109 
Tissue collection and preservation 110 
Canine luteal samples were collected from experimental animals by routine ovariohysterectomy 111 
(OHE) during the non-pregnant luteal phase and pregnancy. The time of ovulation was 112 
determined by regular measurements of P4 concentrations in peripheral blood plasma at 2-3 day 113 
intervals and by vaginal cytology. The day when P4 levels reached at least 5ng/ml was assigned 114 
as the day of ovulation (Concannon et al. 1989). Tissue samples were assigned to the following 115 
groups: 116 
Non-pregnant dogs: post-ovulation (p.o.) day 5 (n=5), day 15 (n=5), day 25 (n=5), day 35 (n=5), 117 
day 45 (n=5) and day 65 (n=5).  118 




Pregnant dogs: pre-implantation (days 8-12, n=5), post-implantation (days 18-25, n=5), mid-119 
gestation (days 35-40, n=5) and prepartum luteolysis (n=3). The day of mating was designated as 120 
day 0 and was 2-3 days after ovulation. In the pre-implantation group, pregnancies were 121 
determined by the presence of embryos in uterine flushings. Prepartum luteolysis was assessed by 122 
regular measurements of circulating P4 concentration at 6h intervals beginning with gestational 123 
day 58; OHE was performed when P4 levels dropped below 3ng/ml in two consecutive 124 
measurements. Additionally, abortions were induced in mid-pregnant dogs with an antigestagen, 125 
Aglepristone (Alizine
®
, Virbac, Bad Oldesloe, Germany; 10mg/Kg bw, 2x/24 h apart) and OHE 126 
was performed 24h (n=5) and 72h (n=5) after the 2nd treatment. All animal procedures were 127 
approved by the respective authorities for animal experiments at Justus Liebig University 128 
Giessen, Germany (permit no. II 25.3-19c20-15c GI 18/14 and VIG3-19c/2015c GI, 18,14) and 129 
by the Faculty of Veterinary Medicine, University of Ankara, Ankara, Turkey (permit no. Ankara 130 
2006/06).  131 
Tissue collection and preservation for immunohistochemistry (IHC) and non-radioactive in situ 132 
hybridization (ISH), protein extraction for Western blot analysis and total RNA isolations for 133 
PCR reactions were performed as described previously (Kowalewski et al. 2010a, Kowalewski et 134 
al. 2011, Gram et al. 2013). Thus, immediately after OHE, CL were trimmed of surrounding 135 
tissues and either placed in 10% neutral phosphate-buffered formalin for 24h at +4°C for IHC 136 
and ISH, or immersed in RNAlater
®
 (Ambion Biotechnology GmbH, Wiesbaden, Germany) for 137 
24 h at +4°C and stored afterwards at -80°C until total RNA isolation or protein extraction.  138 
 139 
Primary luteal cell cultures 140 
Canine primary lutein cells were isolated from CL of clinically healthy bitches (n=15), which 141 
underwent routine OHE early in diestrus, 7-14 days after the clinical signs of heat had ceased, 142 




and were used in our previous study determining the role of PGE2 in regulating canine luteal 143 
steroidogenic acute regulator (STAR) protein expression and steroidogenesis (Kowalewski et al. 144 
2013). The mRNA obtained from that previous study was used in the present investigation to test 145 
the impact of PGE2 treatment on the expression of genes encoding for members of the ET 146 
system. Briefly, cells were isolated using 0.15% Collagenase (Sigma-Aldrich Chemie GmbH, 147 
Buch, CH) and undissociated tissue was removed with a 75µm cell strainer (BD Biosciences, 148 
Basel, CH). Following washing steps with PBS, cells were suspended in culture medium 149 
(DMEM/F12, pH 7.2-7.4, 10% heat-inactivated FBS, 100U/ml penicillin and 100µg/ml 150 
streptomycin, 1% ITS (Insulin-Transferrin-Selenium); all from Chemie Brunschwig, AG, 151 
BASEL, CH), seeded into 6-well plates and maintained in a humidified incubator at 37°C under 152 
5% CO2, until reaching 70-80% confluency. The steroidogenic identity of isolated primary luteal 153 
cells was confirmed by immunocytochemical 3βHSD staining and STAR immunoflorescence 154 
staining (Kowalewski et al. 2013). Only non- trypsinized, “passage 0” cells were used for all 155 
experiments. Before treatments, cells were rinsed with pre-warmed sterile PBS, which was then 156 
replaced by serum-free medium, and used for stimulations with either 0.5 mM N6, 2-157 
dibutyryladenosine-3, 5-cyclic monophosphate (dbcAMP) or 20µM PGE2 (both from Sigma-158 
Aldrich Chemie GmbH) for 6h. After treatment for 6h, upregulated expression of STAR mRNA 159 
and protein, and significantly increased steroidogenic output, were previously observed 160 








Immunohistochemical (IHC) staining was based on our previously published protocol 165 
(Kowalewski et al. 2006a, Kowalewski et al. 2006b). Briefly, formalin-fixed paraffin-embedded 166 
CL tissues were sectioned at 2µm thickness and transferred onto SuperFrost® microscope slides 167 
(Menzel-Glaeser, Braunschweig, Germany), allowed to dry overnight at 37°C, deparaffinized 168 
with xylene and rehydrated through a graded ethanol series. Epitopes were retrieved by 169 
microwave heating in 10mM citrate buffer pH 6.0. Slides were treated with 0.3% hydrogen 170 
peroxide in methanol to remove endogenous peroxidase activity. Then they were overlaid with 171 
10% horse serum, which was used as a blocking serum to reduce non-specific binding, and 172 
incubated overnight at +4°C with primary antibodies. The following primary antibodies were 173 
used: affinity purified goat polyclonal anti-ETA (sc-21194; dilution 1:50), affinity purified goat 174 
polyclonal anti-ETB (sc-21196; dilution 1:100), affinity purified goat polyclonal anti-ECE-1 (sc-175 
27558; dilution 1:300), all from Santa Cruz Biotechnology Inc., CA, USA; and mouse 176 
monoclonal anti-ET-1 (E166; dilution 1:400) purchased from Sigma-Aldrich. As a negative 177 
control, sections were either incubated while omitting the primary antibody, or with non-immune 178 
IgGs of the same species instead of primary antibody (the so-called isotype control) applied at the 179 
same protein concentration. Following incubation of slides with biotin-labelled secondary 180 
antibodies at 1:100 dilution, signal intensity was amplified using the streptavidin-peroxidase 181 
Vectastain ABC kit (Vector Laboratories Inc., Burlingame, CA, USA). The following secondary 182 
antibodies were used: biotinylated horse anti-goat IgG BA-9500, and horse anti-mouse IgG 183 
BA2000 (all from Vector Laboratories Inc.). Peroxidase activity was visualized using the Liquid 184 
DAB+ substrate kit (Dako Schweiz AG, Baar, Switzerland) and slides were counterstained with 185 
hematoxylin. 186 
 187 
Protein preparation and Western blot analysis 188 




Only luteal samples from pregnant dogs were available for Western blot analysis. Tissues were 189 
disrupted while maintaining the cold chain process throughout all procedures and homogenized 190 
in NET-2 lysis buffer (50mM Tris-HCl, pH 7.4, 300mM NaCl, 0.05% NP-40) containing 10µl/ml 191 
protease inhibitor cocktail (Sigma-Aldrich). Following protein extraction, samples were 192 
centrifuged (10,000 X g for 10 min, at 4°C), dissolved in sample buffer (25 mM Tris-Cl, pH 6.8, 193 
1% SDS, 5% β-mercaptoethanol, 10% glycerol, 0.01% bromphenol blue) and SDS-PAGE was 194 
performed using 20 µg of tissue homogenate per lane on 10% SDS-polyacrylamide gel as 195 
described previously (Kowalewski et al. 2010b, Kowalewski et al. 2011, Sprekeler et al. 2012, 196 
Gram et al. 2013). Afterwards, proteins were blotted onto polyvinylidene difluoride (PVDF) 197 
membranes (Bio-Rad Laboratories GmbH, Munich, Germany) and incubated overnight at +4
o
C 198 
with primary antibody diluted in PBS containing 2.5% skimmed milk. Due to the limited 199 
availability of canine-specific or cross-reacting antibodies suitable for Western blot analysis, 200 
experiments were restricted to detecting the ETB receptor. Goat polyclonal affinity-purified anti-201 
human ETB primary antibody (same as for IHC; Santa Cruz Biotechnology) was used at 1:500 202 
dilution. The specificity of the primary antibody was verified by blocking the anti-ETB antibody 203 
with the epitope-specific blocking peptide (sc-21196; Santa Cruz Biotechnology). Following 204 
incubation of membranes with HRP-conjugated secondary donkey anti-goat IgG sc-2056 205 
antibody (Santa Cruz Biotechnology Inc.; dilution 1:15,000), the Immun-Star™ WesternC™ 206 
Chemiluminescent Kit substrate (Bio-Rad) was applied according to the manufacturer's protocols 207 
and signals were detected using the ChemiDoc™ XRS+ System and Image Lab (Bio-Rad). For 208 
internal loading control PVDF membranes were reblotted with monoclonal mouse anti-β-ACTIN 209 
antibody (sc-69879; Santa Cruz Biotechnology, dilution 1:1000); secondary HRP goat anti-210 
mouse IgG (W402B) from Promega, Dübendorf, CH, was used at a dilution of 1: 15,000. ImageJ 211 




software was applied for assessing the density of bands. Parametric one-way analysis of variance 212 
(ANOVA) followed by the Tukey-Kramer multiple comparison test was used to determine the 213 
effect of time on luteal ETB protein expression. The GraphPad 3.06 program (GraphPad 214 
Statistical Software, San Diego, CA, USA) was applied. Numerical data are presented as the 215 
mean ± standard deviation (SD). Representative Western blots are shown. 216 
 217 
Total RNA isolation and Real Time (TaqMan) PCR  218 
Total mRNA was obtained from CL of pregnant and non-pregnant dogs using TRIzol® reagent 219 
following the manufacturer’s directions (Invitrogen, Carlsbad, CA, USA). Concentrations of 220 
isolated RNA were measured using a NanoDrop 2000C
®
 spectrophotometer (Thermo Fisher 221 
Scientific AG, Reinach, CH). DNAse treatment and reverse transcription (RT) were performed 222 
following our previously published protocol (Kowalewski et al. 2006b, Kowalewski et al. 2011). 223 
Then, expression of mRNA in luteal samples was determined by semi-quantitative real time 224 
(TaqMan) PCR using an automated fluorometer (ABI PRISM 7500 Sequence Detection System, 225 
Applied Biosystems, Foster City, CA, USA). The list of primers and TaqMan probes obtained 226 
from Microsynth (Balgach, CH) together with amplicon sizes are presented in Table 1. The 227 
following commercially available TaqMan Gene Expression Assays® from Applied Biosystems 228 
were used: ET-1 (Prod. No. Cf02622421_m1), ET-2 (Prod. No. Cf02622240_m1), ET-3 (Prod. 229 
No. Cf02622419- g1), ECE-1 (Prod. No. Cf02627515_m1) and CYCLOPHILIN A (Prod. No. 230 
Cf03986523-gH). In order to exclude genomic DNA contamination, the so-called “RT-minus 231 
controls” were run (i.e., samples where the RT reaction was omitted). Additional controls 232 
consisted of using autoclaved water instead of cDNA. The reaction mixture for all samples was 233 
prepared as follows: 200nM TaqMan Probe, 300 nM of each primer, 12.5 µl Fast Start Universal 234 
Probe Master (ROX)® (Roche Diagnostics, Mannheim, Germany) and 5µl cDNA corresponding 235 




to 100ng total RNA per sample. All samples were run in duplicates. The thermal cycler steps 236 
were set as follows: denaturation at 95°C for 10 min, 40 cycles at 95°C for 15 sec and 1 cycle at 237 
60°C for 60 sec. Efficiency of each target gene was calculated using the CT slope method and the 238 
relative gene expression was calculated using a comparative CT method (∆∆CT method) 239 
according to the manufacturer’s protocols for the ABI PRISM
®
 7500 Sequence Detection System 240 
(Applied Biosystems) and as described previously (Kowalewski et al. 2006b, Kowalewski et al. 241 
2011), and they were normalized using GAPDH, 18SrRNA and cyclophilin. Selected amplicons 242 
of each gene were sent for commercial sequencing (Microsynth).  243 
The effects of observational group on expression of target genes in luteal samples were tested by 244 
one-way analysis of variance (ANOVA) followed by the Tukey-Kramer multiple comparison 245 
test. For samples obtained from induced abortions, Dunnett’s multiple comparison test was 246 
performed; the results are presented as n-fold change in target expression compared to the 247 
expression at mid-gestation, which served as a non-treated control. In order to test for the effects 248 
of treatment with PGE2 on ET system expression in cell cultures, an unpaired two-tailed 249 
Student’s t-test was performed; numerical data are presented either as Xg ± DF or mean ± SD. 250 
All statistical tests were performed with GraphPad 3.06 software. Numerical data are presented as 251 
the mean ± standard deviation (SD). P < 0.05 was considered statistically significant. 252 
 253 
In situ hybridization (ISH) 254 
Due to the lack of canine-specific antibodies available for ET-2 and ET-3, non-radioactive in-situ 255 
hybridization was used to localize their expression at the level of transcripts. Formalin-fixed, 256 
paraffin-embedded tissues were used and all procedures were performed following our previously 257 
published protocol (Kowalewski et al. 2006a). Primers used for generating cDNA templates for 258 
cRNA synthesis were as follows: ET-2 forward: 5’-ACA TCA TCT GGG TGA ACA CT-3’, ET-259 




2 reverse: 5’-CCT AGG AAA GCG GAT CTT-3’ (amplicon length 262bp), ET-3 forward: 5’-260 
CTA TTG CCA CCT GGA CAT CA -3’, ET-3 reverse: 5’-GCT GGC TCT TCC TCT TTG TC-261 
3’ (amplicon length 258bp). The PCR products were visualized using 2% ethidium bromide-262 
stained agarose gel electrophoresis, isolated using the Qiaex II gel extraction system (Qiagen 263 
GmbH, Hilden, Germany) and subcloned into the pGEM-T vector (Promega). Upon linearization 264 
of plasmids with either NcoI or NotI restriction enzymes (New England Biolabs, Frankfurt, 265 
Germany), cRNA probes were synthesized by in vitro transcription with a DIG-RNA labelling kit 266 
(Roche Diagnostics). Plasmids were sent for commercial sequencing (Microsynth). Following 267 
incubation at 37
o
C overnight, the (DIG) digoxygenin-labeled cRNA probes were detected using 268 
alkaline phosphatase-conjugated sheep anti-DIG Fab Fragments (Roche Diagnostics 269 
International) diluted 1:5000. The signals were visualized using 5-bromo-4-chloro-3-indolyl 270 
phosphate and nitroblue tetrazolium (NBT/BCIP; Roche Diagnostics International) substrate. 271 
 272 
Results 273 
Semi-quantitative assessment of gene expression.  274 
The expression of all target genes was detectable in CL of pregnant and non-pregnant animals at 275 
every luteal stage examined. Whereas the expression of ET-1 mRNA did not change significantly 276 
over time, both in non-pregnant and pregnant animals (P=0.91 and P=0.12, respectively; Fig 1A, 277 
B), the expression of ET-2 and ET-3 was significantly modulated in both situations showing 278 
time-dependent effects, which differed at the end of the luteal lifespan (P=0.01 and P<0.0001 for 279 
ET2, and P<0.0001 and P=0.0003 for ET-3, in non-pregnant and pregnant bitches, respectively). 280 
Thus, the expression of ET-2 mRNA was upregulated during the early luteal phase in pregnant 281 
and non-pregnant animals and suppressed significantly by day 35 after ovulation in non-pregnant 282 
bitches compared with its highest expression at day 15 (P<0.05). In pregnant dogs, ET-2 mRNA 283 




decreased significantly (P<0.05) following implantation. While its expression remained low in 284 
the absence of pregnancy until the end of the observation period (day 65 p.o.) (Fig. 1C), a new 285 
and significant increase (P<0.001) was noted in pregnant animals at the time of prepartum 286 
luteolysis (Fig. 1D). ET-3 mRNA was lowest in early CL, increased gradually with the 287 
development of the CL until the mid-luteal phase, and was significantly elevated during the late 288 
luteal stage in non-pregnant animals (P<0.01 for day 45 vs. day 65 p.o.), or during prepartum 289 
luteolysis in pregnant ones (P<0.05) (Fig. 1E,F). As for ET receptors, ETA was expressed 290 
constantly in CL collected from non-pregnant females and did not change significantly 291 
throughout the luteal phase (P=0.91) (Fig. 2A).  This was in contrast to the situation observed in 292 
pregnant bitches, in which a time-dependent effect was observed (P=0.04); prepartum luteolysis 293 
was associated with strongly upregulated ETA mRNA expression (P<0.05) compared with the 294 
post-implantation stage of pregnancy (Fig. 2B). ETB mRNA was significantly altered over time 295 
(P=0.0001) in both situations, i.e., during gestation and in non-pregnant cyclic dogs. It was 296 
strongly elevated in early CL, followed by a significant decrease, which in non-pregnant animals 297 
was noted at day 25 after ovulation (P<0.001) compared with its highest expression at day 15 298 
p.o.. A further gradual decrease was observed towards day 65 p.o. (P<0.01 compared with day 15 299 
p.o.) (Fig. 2C). In pregnant bitches, ETB decreased significantly at mid-gestation (P<0.01) 300 
compared with the pre-implantation stage of pregnancy, and remained low at prepartum 301 
luteolysis (Fig. 2D). Similarly, at the protein level ETB expression was modulated over time 302 
(P<0.0001), being highest in early CL, and exhibited significantly diminished levels (P<0.001) at 303 
post-implantation and a further decrease (P<0.001) at prepartum luteolysis (Fig. 3B). An 304 
expression pattern resembling that of ETB was observed for ECE-1 (Fig. 2E,F). Also here, the 305 
expression was time-dependent (P=0.0005 and P=0.0008 for pregnant and non pregnant females, 306 
respectively), with the highest mRNA abundance in early CL (Fig. 2E,F). While its expression 307 




had already decreased strongly (P<0.01) by day 15 p.o. in non-pregnant dogs, in pregnant 308 
animals the ECE-1 levels were significantly suppressed (P<0.001) during prepartum luteolysis, 309 
compared with the highest levels noted at the pre-partum stage of pregnancy (Fig. 2E,F).  310 
The effect of treatment with the antigestagen Aglepristone
® 
on luteal ET system expression was 311 
investigated in mid-pregnant dogs (40-45 days of gestation). Non-treated mid-pregnant dogs were 312 
used as negative controls. Besides the elevated (P<0.05) expression of ET-1 (Fig. 4A) and 313 
unaffected (P>0.05) expression of ET-2 (Fig. 4B), the treatment resulted in similar changes to 314 
those observed during normal prepartum luteolysis, i.e., ET-3 and ETA increased significantly 315 
24h after the 2
nd
 treatment (P<0.05 and P<0.01, respectively), while the expression of ETB 316 
remained unchanged (P>0.05) 24h after the 2
nd
 treatment but decreased significantly at 72h 317 
(P<0.01) and ECE-1 remained unaffected (P>0.05) (Fig. 4C-E).  318 
Stimulation of canine lutein cells with 20µM PGE2 over a 6h time course did not affect the 319 
expression of ETA, ET-1 and ECE-1 (P>0.05) (Fig. 5A,C,E). Whereas ET-2 was significantly 320 
decreased (P<0.01) (Fig. 5D), the expression of ETB increased significantly (P<0.05) (Fig. 5B). 321 
In contrast, ET-3 mRNA expression remained below the detection limit.  322 
 323 
Luteal localization of canine ET system expression. 324 
Immunohistochemistry was applied to localize the expression of ET-1, ECE-1, ETA and ETB at 325 
the protein level. Due to the lack of canine-specific anti-ET-2 and anti-ET-3 antibodies, their 326 
expression was assessed by ISH. ET-1 was predominantly targeted to the luteal cells without 327 
marked changes in signal intensity over time in both situations, i.e., in pregnant and non-pregnant 328 
animals (Fig. 6). As for ET-2, its mRNA was predominantly found in capillaries (Fig 7A), while 329 
that of ET-3 was localized in endothelial cells of small and larger luteal vessels (Fig 7B). As for 330 




ECE-1, signals were detectable throughout the luteal phase and strong immune signals were 331 
localized to the vascular endothelial cells, and weaker expression was detected within the luteal 332 
cells (Fig 8). The luteal signals tended to be stronger in early diestrus of pregnant and non-333 
pregnant cyclic animals. No or only weak signals were observed in CL for ETA throughout the 334 
luteal lifespan but became clearly visible during prepartum luteolysis in pregnant females (Fig. 335 
9B) where its localization was targeted to the endothelial cells of capillaries. In contrast, ETB 336 
was clearly detectable and localized in luteal cells, the tunica media of arteries in early CL and 337 
some of the interstitial cells (Fig 10). With the progression of the luteal phase, signal intensity 338 
decreased (Fig. 10) and the weakest staining was observed in capillaries and luteal cells during 339 
late diestrus and at the prepartum luteolysis in pregnant bitches (Fig 10). 340 
 341 
Discussion 342 
In this project we evaluated the expression and localization of the members of the ET system in 343 
luteal samples from non-pregnant dogs, as well as in CL collected at selected stages of 344 
pregnancy, i.e., pre-implantation, post-implantation and mid-gestation, and during normal and 345 
antigestagen-induced prepartum luteolysis/abortion.  346 
Whereas the expression of ET-1, which was abundantly present in luteal cells, did not change 347 
significantly throughout the luteal phase, the early luteal phase of both pregnant and non-348 
pregnant cyclic bitches was characterized by markedly increased levels of vascular ET-2. This 349 
was associated with concomitantly increased expression of ECE-1, which is responsible for 350 
enzymatic activation of ETs. A similar expression pattern of ET-2 was observed in CL of cows 351 
(Klipper et al. 2010), implying a role of this peptide during luteal formation and angiogenesis. 352 
The physiological significance of ET-2 in ovarian function was recently demonstrated in 353 
knockout mice, in which loss of ET-2 expression resulted in impaired ovulation and luteal 354 




formation (Cacioppo et al. 2014). Importantly, ET-2 injection into ovaries of these animals 355 
augmented ovulation and increased expression of the cytochrome P450 side chain cleavage 356 
enzyme (P450scc, CYP11A1) (Cacioppo et al. 2014). Similar effects were observed following 357 
blockage of the ETB receptor in mice, which also resulted in a decrease and/or delay in follicular 358 
rupture (Palanisamy et al. 2006). In the dog, as presented herein, the early luteal development 359 
was associated with strongly increased expression of ETB. Interestingly, its localization seemed 360 
ubiquitous, being targeted to both lutein cells and blood vessels, suggesting a possible functional 361 
interplay between different structural compartments of the CL with the involvement of ET-362 
dependent pathways. The ETB-mediated proliferative and migratory effects of ETs, e.g., ET-1 363 
and ET-3, on endothelial cells and smooth muscles of the vascular tunica media, were shown 364 
previously (Alberts et al. 1994, Morbidelli et al. 1995). Additionally, by activating the nitric 365 
oxide pathway in endothelial cells, ETB is capable of increasing vascular permeability and 366 
inducing vasodilation (Tsukahara et al. 1994). Therefore, ETs exhibit both angiogenic and 367 
vasoactive properties. The latter, i.e., vasodilatory and proliferative capabilities of ETB, could 368 
also apply to early canine CL, which, following ovulation, requires an increased blood supply to 369 
facilitate its rapid growth and enhanced functional steroidogenic performance. During this time, 370 
PGs are among the most important regulators of canine luteal function (Kowalewski et al. 2013, 371 
Kowalewski 2014). Only recently, a functional causality between local PG production and the 372 
steroidogenic activity of canine CL was shown (Kowalewski et al. 2015). Thus, blocking luteal 373 
COX2 (PTGS2) function with a selective blocker, firocoxib (Previcox
®
, Merial Ltd.), resulted in 374 
suppression of luteal PGE2 synthesis and impairment of STAR expression (Kowalewski et al. 375 
2015).  Moreover, the expression of prolactin receptor (PRLR) was diminished in bitches treated 376 
with this COX2 blocker. On the other hand, in canine luteal cells isolated from early diestrous 377 
bitches, PGE2 stimulated PRLR expression, further implying a possible functional relationship 378 




between these two regulatory factors (Kowalewski et al. 2015). This seems to be an important 379 
observation in view of the role of PRL as the predominant luteotropic factor in dogs during the 380 
second half of diestrus (Concannon et al. 1987, Okkens et al. 1990). In line with this, in the 381 
present study, stimulation of canine primary lutein cells with PGE2 significantly upregulated 382 
their ETB mRNA expression. Therefore, besides being directly involved in the regulation of 383 
canine CL function by stimulating STAR expression and increasing P4 output, PGE2 appears to 384 
participate indirectly in maintenance of canine luteal function by enhancing the expression of 385 
PRLR and ETB.  386 
As observed in the present study, the mid and late luteal phases were characterized by decreasing 387 
ETB and ET-2 expression. This was associated with concomitantly increasing levels of ET-3, 388 
which together with ET-2 was predominantly localized in vascular compartments of the CL. 389 
Contrasting with ETB, the potent vasoconstrictor ETA was rather weakly and stably expressed 390 
throughout the luteal phase, while its expression increased significantly along with elevated ET-2 391 
levels during normal prepartum luteolysis. Interestingly, however, for both factors, i.e., ETA and 392 
ET-2, this was not the case during late luteal regression in non-pregnant animals when their 393 
expression remained unchanged.  394 
In the dog, P4 is considered as a luteotropic factor, so that interfering with its function, e.g., by 395 
applying an antigestagen, activates the uterine and placental prostaglandin system and induces a 396 
luteolytic cascade leading to pre-term parturition/abortion (Kowalewski et al. 2009, Kowalewski 397 
et al. 2010a). Accordingly, except for the upregulated ET-1 and unaffected ET-2 expression, 398 
application of an antigestagen on days 40-45 of gestation, which is a time point distant from 399 
physiological parturition, evoked similar changes to those observed during prepartum luteolysis. 400 
These changes refer especially to the upregulated expression of ETA, indicating the involvement 401 
of P4 signaling in this process. Interestingly, as shown in this study, while the expression of the 402 




vasoactive ET system reveals strong spatio-temporal changes at the end of canine pregnancy, the 403 
angiogenic VEGF-system does not change significantly during normal and induced 404 
parturition/abortion (Kowalewski 2014). Therefore, cumulatively, it seems plausible that in 405 
contrast to non-pregnant dogs, vascular functionality strongly contribute to structural and 406 
functional luteolysis in dogs at term, likely due to the PGF2α-induced and ET-mediated 407 
vasoconstrictor properties of ETA. The prolonged, slow process of luteal regression observed in 408 
non-pregnant animals remains primarily a passive one, at least where vascular activity is 409 
concerned.  410 
For conclusion, the role of the ET system during the cessation of luteal function seems to diverge 411 
between pregnant and non-pregnant dogs, i.e., being actively regulated, it possibly contributes to 412 
the prepartum luteolysis. Its function also differs from the role of the VEGF system, which 413 
remains unaffected in both situations (Kowalewski 2014). The role of PGE2 as an important 414 
luteotropic factor has been further strengthened by results obtained from our in vitro experiments 415 
with canine lutein cell cultures, in which PGE2 was found to be a positive regulator of ETB 416 
expression.  417 
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Figure Legends 1 
Figure 1. 2 
Time-dependent expression of canine endothelins (ET) -1, -2 and -3 as determined by Real Time 3 
(TaqMan) PCR (mean ± SD). (A, C, E)  CL of non-pregnant dogs (days (d) 5-65 post-ovulation), 4 
and (B, D, F) CL of pregnant dogs. Bars with different letters differ at P<0.05. 5 
 6 
Figure 2. 7 
Expression of endothelin receptors -A and -B (ETA and ETB) and endothelin converting enzyme 8 
1 (ECE-1) as determined by Real Time (TaqMan) PCR (mean ± SD) in the (A, C, E) CL from 9 
non-pregnant dogs (days (d) 5-65 post ovulation), and (B, D, F) CL collected at selected stages of 10 
pregnancy and during prepartum luteolysis. Bars with different letters differ either at P<0.05 in 11 
B, or at P< 0.01 in D and E, or P<0.001 in F. 12 
 13 
Figure 3. 14 
The expression of endothelin receptor B (ETB) (approx. 50 kDa) was determined by western blot 15 
analysis. Representative immunoblots are shown. (A) The epitope-blocking peptide was used to 16 
quench the ETB-specific signal in a luteal tissue homogenate derived from pre-implantation CL. 17 
(B) Expression profile of ETB protein in CL collected at selected stages of pregnancy and during 18 
prepartum luteolysis; 20µg protein was used for each sample. Membranes were re-blotted with β-19 
ACTIN (45 kDa), which served as an internal loading control. Lower panel in (B) represents 20 
densitometric values (standardized optical density; SOD) for ETB expression normalized against 21 
β-ACTIN. All numerical data are presented as the means ± SD. Bars with different letters differ 22 
at P<0.001. M=molecular weight marker. 23 
 24 




Figure 4. 25 
Expression of endothelin system members (ET-1, -2, -3, ETA, ETB and ECE-1) as determined by 26 
Real Time (TaqMan) PCR (mean ± SD) during antigestagen (Aglepristone
®
)-induced 27 
luteolysis/abortion compared with the mid-gestation group used as a non-treated control. Bars 28 
with different asterisks differ at P<0.05.  29 
 30 
Figure 5. 31 
Effect of PGE2 on expression of endothelin system members in canine primary luteal cells 32 
collected from non-pregnant dogs during the early CL phase. Cells were cultured in serum-free 33 
DMEM/F12 medium with 20µM PGE2. Non-stimulated cells served as a negative control. (A-E) 34 
endothelin receptors -A and -B (ETA and ETB) and endothelins (ET) -1 and -2 mRNA 35 
expression as determined by real-time (TaqMan) PCR normalized against cyclophilin A, GAPDH 36 
and 18SrRNA. 37 
 38 
Figure 6. 39 
Immunohistochemical localization of ET-1 in the canine CL at selected time points of pregnancy 40 
and on days 5 and 65 post-ovulation in non-pregnant animals. (A) pre-implantation stage, (B) 41 
post-implantation, (C) mid-gestation, (D) prepartum luteolysis, and on days (E) 15 and (F) 65 42 
post-ovulation in non-pregnant animals. (A-F) ET-1 is localized to the luteal cells (open arrows) 43 








Figure 7. 48 
Localization of ET-2 and ET-3 mRNA in the canine CL during prepartum luteolysis by in situ 49 
hybridization (ISH). (A) ET-2 mRNA is localized to the capillary endothelial cells (solid 50 
arrowheads). (B) ET-3 mRNA is localized in vascular endothelial cells (solid arrowheads) and 51 
luteal cells (open arrows). There is no background staining in the negative controls (insert to A 52 
and B). 53 
 54 
Figure 8. 55 
Immunohistochemical localization of endothelin converting enzyme 1 (ECE-1) in the CL of 56 
pregnant dogs at selected periods of pregnancy and on days 5 and 15 post-ovulation in non-57 
pregnant animals. (A) Pre-implantation stage, (B) post-implantation, (C) mid-gestation (D) 58 
prepartum luteolysis, and on days (E) 5 and (F) 15 post-ovulation in non-pregnant animals. (A-F) 59 
ECE-1 expression is localized in luteal cells (open arrows) and vascular endothelial cells (solid 60 
arrowheads). There is no background staining in the isotype control (insert to F) 61 
 62 
Figure 9. 63 
Immunohistochemical localization of endothelin receptors A (ETA) in CL of pregnant dogs at 64 
selected time points of pregnancy, and on days 5 and 65 post-ovulation in non-pregnant animals. 65 
(A) Pre-implantation stage, (B) during prepartum luteolysis, and on days (C) 5 and (D) 65 post-66 
ovulation in non-pregnant animals. (A) No or only weak signals were observed during pregnancy 67 
in luteal tissue (pre-implantation stage shown). (B) Strong signals were localized in the capillary 68 
endothelial cells (solid arrows) during prepartum luteolysis. The capillary endothelial cell 69 
expression of ETA is shown at higher magnification in the insert to B. There was no or only 70 




weak staining throughout the non-pregnant diestrus (shown at days 5 and 65 post-ovulation). 71 
There is no background staining in the isotype control (insert to D). 72 
 73 
Figure 10. 74 
Immunohistochemical localization of endothelin receptors B (ETB) in the CL of pregnant dogs 75 
during pregnancy and on days 5 and 65 post-ovulation in non-pregnant bitches. (A) pre-76 
implantation stage, (B) post-implantation, (C) mid-gestation (D) prepartum luteolysis, and on 77 
days (E) 5 and (F) 65 post-ovulation in non-pregnant bitches. (A) During pre-implantation, luteal 78 
ETB expression is localized to the luteal cells (open arrows), tunica media of arteries (solid 79 
arrowheads) and interstitial cells (open arrowheads). (B) At post-implantation and (C) mid-80 
gestation, luteal signals are localized in luteal cells (open arrows) and interstitial cells (open 81 
arrowheads in B). (D) During prepartum luteolysis, signals are localized in luteal cells (open 82 
arrows) and capillary pericytes (solid arrows). During day (E) 5 post-ovulation in non-pregnant 83 
animals, ETB expression is localized to the luteal cells (open arrows) and tunica media of arteries 84 
(solid arrowhead). At (F) day 65 post-ovulation in non-pregnant animals, signals are localized in 85 
luteal cells (open arrows) and capillary pericytes (solid arrow). There is no background staining 86 
in the isotype control (insert to F). 87 
 88 
Table1 89 
List of primers and TaqMan Probes used for semi-quantitative RT-PCR 90 
 91 
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Primer Accession 
Numbers 
Primer Sequences Product 
Length 
GAPDH AB028142 Forward: 5’-GCT GCC AAA TAT GAC GAC ATC A-3’ 
Reverse: 5’-GTA GCC CAG GAT GCC TTT GAG-3’ 
TaqMan probe: 5’-TCC CTC CGA TGC CTG CTT CAC TAC CTT-3’ 
75bp 
18SrRNA FJ797658 Forward: 5’-GTC GCT CGC TCC TCT CCT ACT-3’ 
Reverse: 5’-GGC TGA CCG GGT TGG TTT-3’ 
TaqMan probe: 5’-ACA TGC CGA CGG GCG CTG AC-3’ 
125bp 
ETA NM_001031632.1 Forward:5’-GGC CCCAAC GCA CTG ATA-3’ 
Reverse:5’-CCC GCC AGA AGC TTA AAC AC-3’ 
TaqMan probe:5’-CCA GCC TTG CCC TTG GAG ACC TTA TC-3’ 
92bp 
ETB NM_001010943.2 Forward: 5’-CAT CAT CGG GAA CTC CAC ACT-3’ 
Reverse:5’-CAG AGC CAG GCT GGC TAT CA-3’ 
TaqMan probe:5’-CAA GAA CAA GTG CAT GCG AAA CGG C-3’ 
91bp 
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